Proxima, Varian Sign MammoSource HDR Brachytherapy Agreement
This article was originally published in The Gray Sheet
Executive Summary
Proxima's 26 sales reps will market Varian Medical System's MammoSource high-dose-rate brachytherapy afterloader for use with the firm's MammoSite breast cancer treatment catheter
You may also be interested in...
Proxima, Laserscope, Medtronic Qualify For Improved Outpatient Payments
Adoption of Proxima Therapeutics' MammoSite high-dose rate brachytherapy catheter for early-stage breast cancer will increase with its placement into a new-technology APC, the firm maintains
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.